Ariadne — Safety, Research, Risks & Legal Status

Not medical advice. Ariadne is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	4C-D; 4C-DOM; BL-3912A; 2-amino-1-(2,5-dimethoxy-4-methylphenyl)butane
Category	Research Chemical
Developer	Bristol-Myers Squibb (BL-3912A designation), with original synthesis by Alexander Shulgin (1968)
Development stage	Phase II/III (mid-1970s, discontinued); no active trials; no approved indication
5-HT2A EC50	Approximately 149 nM; maximal efficacy approximately 83% relative to serotonin (in vitro, 2022-2023 data)
Key structural feature	Alpha-ethyl substitution vs. DOM's alpha-methyl - proposed basis for reduced hallucinogenic activity
Published clinical data	None peer-reviewed; available evidence derives from unpublished industry trial summaries relayed through secondary sources
Scheduling status (US)	Not explicitly listed; legal status ambiguous under phenethylamine analog provisions of the CSA
US legal status	Not explicitly scheduled as a standalone compound in the US, but likely subject to analog or positional-isomer provisions under the Controlled Substances Act due to structural similarity to DOET and other Schedule I phenethylamines. Status is legally ambiguous and jurisdiction-dependent. Not approved, not marketed, not in active clinical development. Not for human consumption outside of a formal clinical or research context.

What is Ariadne?

Ariadne (BL-3912A) is a synthetic phenylalkylamine synthesized by Alexander Shulgin in 1968 and subsequently developed by Bristol-Myers Squibb in the early 1970s. It is structurally related to DOM (2,5-dimethoxy-4-methylamphetamine) but carries an alpha-ethyl substitution in place of DOM's alpha-methyl group, a modification that appears to dramatically reduce hallucinogenic potential while preserving serotonergic receptor activity. It reached Phase II/III clinical trials in the mid-1970s for psychiatric and neurological indications before development was discontinued for undisclosed business and regulatory reasons, not for documented safety or efficacy failure. Available clinical data are incomplete and were never formally published in peer-reviewed journals.

How it works

Selective partial agonist at serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. The alpha-ethyl extension relative to DOM reduces both potency (EC50 approximately 149 nM at 5-HT2A) and maximal efficacy (approximately 83% relative to serotonin in functional assays). This partial agonism profile and biased intracellular signaling - distinct from classical full agonists such as LSD or DOI - is hypothesized to underlie the absence of hallucinations. The precise signaling pathways responsible for the dissociation between hallucinogenic and potential therapeutic effects remain under active investigation in preclinical models.

Background & history

Synthesized by Alexander Shulgin in 1968 during his systematic exploration of phenylalkylamines. Bristol-Myers Squibb licensed or internally developed the compound under the designation BL-3912A and initiated human trials approximately 1974. Phase II completion was reported; Phase III initiation was suggested in secondary sources, though documentation is sparse. Development was halted in the mid-to-late 1970s, a period of heightened regulatory pressure on psychoactive drug development following the Controlled Substances Act of 1970. Shulgin later documented the compound in secondary literature. Academic interest was largely dormant until a 2022-2023 ACS Chemical Neuroscience paper and accompanying Columbia University press coverage revived discussion of non-hallucinogenic 5-HT2A agonism as a therapeutic concept.

What the research says

Clinical development by Bristol-Myers Squibb (Squibb Division / Bristol Laboratories) produced internal trial summaries from approximately 1974-1975 describing results in schizophrenia, Parkinson's disease, geriatric cognitive decline, and catatonia. These reports, which circulated through Shulgin's network and secondary sources, describe striking positive outcomes - including near-normal behavior in psychotic patients and complete Parkinson's symptom remission in at least two cases - at doses of 50-300 mg/day with no observed hallucinogenic effects. However, the original trial data were never peer-reviewed or formally published, and independent replication did not occur. The absence of disclosed adverse event data reflects incomplete reporting rather than a proven safety profile. Renewed academic interest emerged circa 2022-2023 when researchers at Columbia University and collaborating institutions published mechanistic work in ACS Chemical Neuroscience examining Ariadne's biased signaling properties and partial agonism profile, framing it as a model compound for non-hallucinogenic 5-HT2A pharmacology. No active clinical trials are registered (trials predate the 2005 ClinicalTrials.gov requirement). The compound currently has no approved indication in any jurisdiction.

Reported effects

Reported absence of hallucinogenic or perceptual distortion effects even at high doses (300 mg) in human trial summaries - not independently verified
Serotonin 5-HT2A/2B/2C partial agonism in receptor binding and functional assays (in vitro, confirmed 2022-2023)
Antipsychotic-like effects reported in unverified 1970s trial summaries in schizophrenia patients
Apparent antiparkinsonian effects reported in at least two cases in unverified trial summaries
Reported cognitive and alertness improvements in geriatric patients in unverified trial summaries
Catatonia relaxation reported in trial summaries - not independently verified
Full pharmacological profile in humans is unknown given absence of published clinical data

Dosing & administration (informational)

The 1974-1975 Bristol-Myers Squibb trial summaries, cited in secondary sources, describe dose ranges of approximately 50-300 mg/day in various patient populations. These figures appear in unpublished industry documents relayed through secondary literature and have not been peer-reviewed. They are provided here for reference purposes only. No safe or effective dose has been established for any indication. Consult a licensed clinician before using any serotonergic agent.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No serious adverse events are described in available secondary accounts of the 1970s trials, but original safety data were never published and cannot be independently evaluated
Absence of reported hallucinogenic effects at doses up to 300 mg is a notable finding, but derives from unpublished industry data
5-HT2B agonism is a pharmacological flag - sustained 5-HT2B activation has been associated with cardiac valvulopathy in other drug classes (e.g., fenfluramine); relevance to Ariadne's exposure levels is unknown
No long-term safety data exist in any published form
Drug-drug interaction profile is essentially uncharacterized
Genotoxicity, reproductive toxicity, and carcinogenicity data are not available in the public literature
Legal ambiguity creates supply and purity risk for any non-clinical acquisition

Drug & supplement interactions

S
e
r
o
t
o
n
e
r
g
i
c
m
e
c
h
a
n
i
s
m
s
s
u
g
g
e
s
t
p
o
t
e
n
t
i
a
l
f
o
r
p
h
a
r
m
a
c
o
d
y
n
a
m
i
c
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
o
t
h
e
r
s
e
r
o
t
o
n
e
r
g
i
c
a
g
e
n
t
s
(
S
S
R
I
s
,
S
N
R
I
s
,
M
A
O
I
s
,
t
r
i
p
t
a
n
s
,
o
t
h
e
r
5
-
H
T
2
l
i
g
a
n
d
s
)
i
n
c
l
u
d
i
n
g
r
i
s
k
o
f
s
e
r
o
t
o
n
i
n
s
y
n
d
r
o
m
e
.
5
-
H
T
2
B
a
c
t
i
v
i
t
y
m
a
y
c
o
m
p
o
u
n
d
c
a
r
d
i
o
v
a
s
c
u
l
a
r
r
i
s
k
w
i
t
h
o
t
h
e
r
a
g
e
n
t
s
a
f
f
e
c
t
i
n
g
c
a
r
d
i
a
c
v
a
l
v
e
s
o
r
s
e
r
o
t
o
n
i
n
-
m
e
d
i
a
t
e
d
v
a
s
o
m
o
t
o
r
t
o
n
e
.
N
o
s
y
s
t
e
m
a
t
i
c
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
.
T
h
e
i
n
t
e
r
a
c
t
i
o
n
p
r
o
f
i
l
e
i
s
e
s
s
e
n
t
i
a
l
l
y
u
n
k
n
o
w
n
.

Who should avoid it

Combination with MAOIs - serotonin syndrome risk
Combination with SSRIs, SNRIs, or other serotonergic agents without clinical supervision
Use in patients with personal or family history of cardiac valvulopathy given theoretical 5-HT2B concern
Use in pregnancy or lactation - no safety data
Use by individuals with psychotic spectrum disorders outside of supervised clinical settings
Sourcing from unverified vendors given absence of supply-chain standards

How it is commonly combined

No stacking data exist. Combination with other serotonergic compounds carries theoretical additive or synergistic risk. No research supports any combination protocol.

Legal & regulatory. Not explicitly scheduled as a standalone compound in the US, but likely subject to analog or positional-isomer provisions under the Controlled Substances Act due to structural similarity to DOET and other Schedule I phenethylamines. Status is legally ambiguous and jurisdiction-dependent. Not approved, not marketed, not in active clinical development. Not for human consumption outside of a formal clinical or research context.

Quality & harm reduction

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find Ariadne →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is Ariadne a psychedelic?

Ariadne is pharmacologically classified as a non-hallucinogenic phenylalkylamine. It shares receptor targets (5-HT2A/2B/2C partial agonism) with classical psychedelics but its partial agonism profile and biased signaling appear to dissociate hallucinogenic effects from serotonergic activity. The 1970s trial summaries report no hallucinogenic effects at doses up to 300 mg; however, these data were never published or independently replicated.

Did Ariadne ever reach human clinical trials?

Yes. Bristol-Myers Squibb conducted trials in the mid-1970s (approximately 1974-1975) that reportedly reached Phase II completion and possibly Phase III initiation. The data were never formally published. The trials predated the ClinicalTrials.gov registry by approximately 30 years, so no official record exists.

Why was development discontinued?

Secondary sources attribute discontinuation to business and regulatory strategy in the post-Controlled Substances Act environment of the 1970s, not to documented safety or efficacy failure. The specific internal rationale has not been publicly disclosed by Bristol-Myers Squibb.

What is the current legal status in the United States?

Ambiguous. Ariadne is not explicitly listed as a Schedule I controlled substance by name, but it may be captured as a positional isomer of DOET or under analog provisions of the Controlled Substances Act. Anyone handling or researching this compound should obtain independent legal counsel before proceeding.

What is the recommended dose of Ariadne?

No dose recommendation can be made. Published trial data establishing a safe or effective dose range do not exist. The figures cited in secondary literature (50-300 mg/day) come from unverified, unpublished industry summaries. Consult a licensed clinician before using any serotonergic compound.

Is there renewed clinical interest in Ariadne?

There is renewed academic and preclinical interest following 2022-2023 mechanistic work published in ACS Chemical Neuroscience and covered by Columbia University news. This research examines Ariadne as a model for non-hallucinogenic 5-HT2A pharmacology. No new human trials have been registered or announced as of the knowledge cutoff.

References & further reading

PubMed: Ariadne 5-HT2A partial agonist phenylalkylamine non-hallucinogenic
PubMed: ACS Chemical Neuroscience 2022 non-hallucinogenic 5-HT2A agonist biased signaling
PubMed: DOM alpha-ethyl analog serotonin receptor efficacy
ClinicalTrials.gov: No records found for Ariadne or BL-3912A (trials predate 2005 registry requirement)
Columbia University News (2023): 'New Article Shows Promise of a Psychedelic Without the Hallucinations' - academic commentary on 2022-2023 mechanistic research